JP2023549055A - 複素環式スピロ化合物及びその使用方法 - Google Patents

複素環式スピロ化合物及びその使用方法 Download PDF

Info

Publication number
JP2023549055A
JP2023549055A JP2023524901A JP2023524901A JP2023549055A JP 2023549055 A JP2023549055 A JP 2023549055A JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023549055 A JP2023549055 A JP 2023549055A
Authority
JP
Japan
Prior art keywords
amino
methyl
diazaspiro
octan
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549055A5 (https=
Inventor
ランマン，ブライアン・アラン
バナジー，アビシェク
チュウ－モイアー，マーガレット
ダイ，ドンチュン
カラー，マシュー・アール
ロペス，パトリシア
マー，ブー・バン
マノーニ，フランチェスコ
メディナ，ホセ・エム
ピックレル，アレクサンダー・ジェイ
タマヨ，ヌリア・エイ
ジュウ，カイ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023549055A publication Critical patent/JP2023549055A/ja
Publication of JP2023549055A5 publication Critical patent/JP2023549055A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023524901A 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法 Pending JP2023549055A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020123913 2020-10-27
CNPCT/CN2020/123913 2020-10-27
PCT/US2021/056702 WO2022093856A1 (en) 2020-10-27 2021-10-26 Heterocyclic spiro compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2023549055A true JP2023549055A (ja) 2023-11-22
JP2023549055A5 JP2023549055A5 (https=) 2024-11-05

Family

ID=78650109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524901A Pending JP2023549055A (ja) 2020-10-27 2021-10-26 複素環式スピロ化合物及びその使用方法

Country Status (7)

Country Link
US (1) US20230406860A1 (https=)
EP (1) EP4237086A1 (https=)
JP (1) JP2023549055A (https=)
AU (1) AU2021370660A1 (https=)
CA (1) CA3199082A1 (https=)
MX (1) MX2023004802A (https=)
WO (1) WO2022093856A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
JP2023544450A (ja) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド 三環式ピリドン及びピリミドン
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
IL310291A (en) 2021-07-23 2024-03-01 Theras Inc Compositions and methods for inhibition of ras
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
AR128212A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
CN117186107A (zh) * 2022-05-31 2023-12-08 成都先导药物开发股份有限公司 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法
CN120659773A (zh) 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
JP2018513853A (ja) * 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2018140514A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2020028706A1 (en) * 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020113071A1 (en) * 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017691A1 (en) 2006-08-10 2008-02-14 Glaxo Group Limited Pyridine derivatives as sodium channel blockers
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
JP2022513967A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
JP7686559B2 (ja) 2018-12-20 2025-06-02 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
JP2018513853A (ja) * 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2018140514A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2020028706A1 (en) * 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020113071A1 (en) * 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Also Published As

Publication number Publication date
US20230406860A1 (en) 2023-12-21
MX2023004802A (es) 2023-06-22
WO2022093856A1 (en) 2022-05-05
EP4237086A1 (en) 2023-09-06
AU2021370660A1 (en) 2023-06-08
CA3199082A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
JP2024532735A (ja) 複素環式化合物及び使用方法
US20250059205A1 (en) Heterocyclic Compounds and Methods of Use
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2025508702A (ja) キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用
JP2024517693A (ja) ２－アミノベンゾチアゾール化合物及びその使用方法
US20250179077A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
JP2024532734A (ja) 複素環式化合物及び使用方法
AU2022219987A1 (en) Cdk inhibitors and methods of use thereof
CN117561063A (zh) 杂环化合物及使用方法
CN117897159A (zh) 杂环化合物及使用方法
CN117835976A (zh) 杂环化合物及使用方法
CN116249696A (zh) 嘧啶酮类化合物及其用途
HK40070481B (en) Fgfr inhibitors and methods of use thereof
HK40070481A (en) Fgfr inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331